about
Identification of a prodromal period in Crohn's disease but not ulcerative colitisMeasuring response in the gastrointestinal tract in systemic sclerosisBiomarkers of Irritable Bowel SyndromeRifaximin therapy for patients with irritable bowel syndrome without constipationRisk of inflammatory bowel disease following a diagnosis of irritable bowel syndromeMethane and the gastrointestinal tract.Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance.Placebo effect in clinical trial design for irritable bowel syndromeThe Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting.Psychological disorders in gastrointestinal disease: epiphenomenon, cause or consequence?Inflammation and microflora.Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.Abnormal breath testing in IBS: a meta-analysis.The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome.Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux.The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.Studying the overlap between IBS and GERD: a systematic review of the literature.Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.A systematic review of diagnostic tests for small intestinal bacterial overgrowth.Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness.Antibiotics for irritable bowel syndrome: rationale and current evidence.Healthy control subjects are poorly defined in case-control studies of irritable bowel syndromeCase studies of antibiotic therapy in the management of functional gastrointestinal disorders.Apple sauce improves detection of esophageal motor dysfunction during high-resolution manometry evaluation of dysphagia.Gas and the microbiome.Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.A 14-day elemental diet is highly effective in normalizing the lactulose breath test.Antibiotics for the treatment of irritable bowel syndromeIntestinal methane production in obese individuals is associated with a higher body mass indexBreath Testing for Small Intestinal Bacterial Overgrowth: Should We Bother?Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage.Measurement of gastrointestinal transit.Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth.Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: presentation of a rare manifestation and review of the literatureMetabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity.Bacterial concepts in irritable bowel syndrome.Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do.A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.Lactose intolerance and the role of the lactose breath test.
P50
Q22242350-7625E74C-5CC3-480F-95CE-339C72FC83C5Q27022416-528C6994-01B8-40E8-B876-AA2B31B606BAQ28069902-78D581FE-AC54-4DBC-8B99-565C6AA6DA19Q28302405-C81EB993-5A50-4257-8F80-7AD72A47ED4CQ31062841-858D07CE-529C-4633-B230-2EC109D5D3F3Q33443954-2EF75FB3-0C5A-4AE6-85B1-C8C30448BAF4Q33459081-2F745619-51C5-4F7D-B0A2-D953A3E38D85Q33586880-93988EBF-5BED-4C43-9CDA-2834A8128A6CQ33688135-F963B4F7-5E4C-4183-A1A0-F7EB9352C27FQ33813422-C45EFA00-6EC1-4213-92D1-E98E154A9B02Q33824492-52437F91-1560-42EE-91EB-546E1A4C3B92Q33916182-DD933995-2ACD-4AB9-A20C-AE25E7E5891AQ34115362-8E168EEF-63E3-44FC-A20B-94D10C8D65B8Q34248518-1D597BC6-B6C5-4E54-8025-563222A44015Q34449503-AAB46BC6-EC53-4980-86D0-2B6D96B758FDQ34548906-D2F2517D-9B4B-4CC7-B44F-6B30132FAEC8Q34574085-A7E62B7C-2E44-4B67-BFB9-8F4EED85223EQ34578629-FBBC5AA5-2677-4985-9F61-5877B2AE8924Q34579745-AC91F7AB-E8E4-455C-967C-35DA419EF024Q34584713-1271DCB3-A9E8-4764-A8BE-DC46AF79A277Q34627613-80D77C19-3203-4F6B-AB1F-52D22B456793Q34642080-8E86EBF6-9300-4289-BFC9-9E11008F5A30Q34907508-714A6C42-1E9A-4FD1-A5CC-1E94B829305FQ34985950-A1CFC44D-5CF1-4ECE-9921-FB33B944EC64Q34990573-EDF80843-AD40-4357-A8CE-296722647F7DQ35024458-4BDB492A-40AB-4C55-AB33-C8BF42A84C3EQ35603014-C05D911B-5763-47A4-AC54-9254E01FA8F4Q35678957-BE659A9D-1987-46C5-9BDC-B1239A5E0030Q35691133-190ECD6A-4BF7-4306-9845-AFC97FAF644FQ35749939-826F8ABA-9795-4FFC-96E4-417CE849D735Q35931566-7AF4CB1E-9125-4341-BC69-0AAF0E908815Q36073385-AE5586E8-B8BF-42CB-A798-763645AE4C79Q36178630-4AEBD6C0-28C3-44FC-940A-BFC2089D8545Q36534298-932B2C05-D8A6-45C3-B6B2-2062A6749186Q36599319-0B729F0F-EB48-4BF4-BB8F-FBADE8DEB156Q36625912-80D7133E-F90E-4FD2-A096-F81ACBCA5701Q36916612-77349779-6ECD-4E23-8148-98651D822156Q36924485-1DA3DA7F-19A6-4A16-9B2B-3ACD1D761492Q37649460-0E6AE5B8-96AA-47C5-A0F4-D8FC1E1C49EFQ37777958-18CEBFE0-0678-40F9-9F7D-6200F5FB03FE
P50
name
Mark Pimentel
@ast
Mark Pimentel
@en
Mark Pimentel
@nl
type
label
Mark Pimentel
@ast
Mark Pimentel
@en
Mark Pimentel
@nl
prefLabel
Mark Pimentel
@ast
Mark Pimentel
@en
Mark Pimentel
@nl
P214
20147425875545040008
P31
P734
P7859
lccn-n2006067744